Fig1 Li JofPharmAnal2020 10-2.jpg: Difference between revisions

Latest revision as of 11:16, 20 June 2024

Description	Graphical abstract Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence of SARS-CoV-2 has been marked as the third introduction of a highly pathogenic coronavirus into the human population after the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) in the twenty-first century. In this minireview, we provide a brief introduction of the general features of SARS-CoV-2 and discuss current knowledge of molecular immune pathogenesis, diagnosis and treatment of COVID-19 on the base of the present understanding of SARS-CoV and MERS-CoV infections, which may be helpful in offering novel insights and potential therapeutic targets for combating the SARS-CoV-2 infection.
Source	Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. (2020). "Molecular immune pathogenesis and diagnosis of COVID-19". Journal of Pharmaceutical Analysis 10 (2): 102–8. doi:10.1016/j.jpha.2020.03.001.
Date	2020
Author	Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S.
Permission (Reusing this file)	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Other versions

Click on a date/time to view the file as it appeared at that time.

	Date/Time	Thumbnail	Dimensions	User	Comment
current	11:16, 20 June 2024		1,179 × 886 (325 KB)	Shawndouglas (talk \| contribs)

You cannot overwrite this file.

The following 2 pages use this file:

This file contains additional information, probably added from the digital camera or scanner used to create or digitize it.

If the file has been modified from its original state, some details may not fully reflect the modified file.

JPEG file comment	HiRes

@@ Line 1: / Line 1: @@
+==Summary==
+{{Information
+|Description='''Graphical abstract''' Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence of SARS-CoV-2 has been marked as the third introduction of a highly pathogenic coronavirus into the human population after the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) in the twenty-first century. In this minireview, we provide a brief introduction of the general features of SARS-CoV-2 and discuss current knowledge of molecular immune pathogenesis, diagnosis and treatment of COVID-19 on the base of the present understanding of SARS-CoV and MERS-CoV infections, which may be helpful in offering novel insights and potential therapeutic targets for combating the SARS-CoV-2 infection.
+|Source={{cite journal |title=Molecular immune pathogenesis and diagnosis of COVID-19 |journal=Journal of Pharmaceutical Analysis |author=Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. |volume=10 |issue=2 |pages=102–8 |year=2020 |doi=10.1016/j.jpha.2020.03.001}}
+|Author=Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S.
+|Date=2020
+|Permission=[https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International]
+}}